Is There a Vaccine for the Bubonic Plague?

No plague vaccine is currently approved or commercially available for general human use anywhere in the world, despite more than a century of attempts to develop one.¹ Older vaccines did exist and were used in limited settings, but all were eventually shelved because of side effects, narrow protection, or both. Several promising candidates are now in clinical trials, including subunit vaccines and, more recently, mRNA-based approaches, but none has yet crossed the finish line into routine use.

Why Plague Still Demands a Vaccine

Plague, caused by the bacterium Yersinia pestis, is far from a historical curiosity. It persists in rodent populations on multiple continents, and fleas transmit it to humans, typically producing the swollen, painful lymph nodes called buboes that define bubonic plague.² If the infection reaches the lungs or blood, it becomes pneumonic or septicemic plague, both of which are far more dangerous. Pneumonic plague can also spread directly between people through respiratory droplets, raising the prospect of person-to-person outbreaks.

Madagascar is the hardest-hit country today. Between 1998 and 2016, authorities there recorded over 13,000 suspected plague cases, with the overwhelming majority being bubonic, though about 7 percent were pneumonic.³ A 2017 outbreak in Madagascar was especially alarming because more than three-quarters of cases were the pneumonic form, which is unusual and harder to contain.⁴ Smaller numbers of human cases occur regularly in parts of Africa, Central Asia, and even the western United States.

Antibiotics can treat bubonic plague effectively when caught early, but pneumonic plague is a different story. Even with antibiotic therapy, pneumonic plague frequently kills.⁵ Making matters worse, extensively antibiotic-resistant strains of Y. pestis have been identified, and their potential for deliberate misuse is a serious biodefense concern.⁶ The World Health Organization has flagged the need for new-generation plague vaccines as urgent. A working vaccine would help protect people in endemic regions, frontline health workers during outbreaks, and military and laboratory personnel who face elevated risk.

The Vaccines That Used to Exist

The first plague vaccine was developed in the 1890s by Waldemar Haffkine, who produced it in Bombay during a pandemic wave that hit British India. Large-scale inoculation programs followed.⁷ By modern standards, Haffkine’s vaccine was crude, essentially heat-killed whole bacteria. Variations on that formula persisted for decades.

The most widely known modern predecessor was the formalin-killed whole-cell vaccine called Plague Vaccine, USP, developed and licensed in the United States. It was given to American military personnel during the Vietnam War and offered meaningful protection against bubonic plague. But it was highly reactogenic, meaning it caused substantial side effects, and it failed to protect against pneumonic plague. It also did not confer long-term immunity.⁸ For a disease whose most lethal form is pneumonic, that gap mattered enormously. The vaccine was eventually withdrawn from use.

In parallel, a live attenuated vaccine strain called EV76 saw widespread use in parts of the former Soviet Union and some other countries. In animal studies, EV76 provided stronger protection against higher challenge doses than the killed vaccine, but immunized animals showed side effects of varying severity.⁹ Versions of the EV76 live vaccine are still used in some Central Asian countries. A study of people receiving the live vaccine in Kazakhstan found that antibody levels in first-time recipients peaked around four months after vaccination, then dropped sharply by eight months and fell again by twelve months. People who had been vaccinated before held onto protective antibody levels somewhat longer, but the pattern still pointed to waning immunity over a year or so.¹⁰ This short shelf life of immunity is one of the recurring headaches in plague vaccinology.

The Leading Candidates Today

The most advanced candidates in the current pipeline are subunit vaccines built around two proteins from Y. pestis: the F1 capsule antigen and the V antigen (also called LcrV), a virulence factor the bacterium uses to attack host cells. These two proteins can be administered together as separate components (F1 + V) or fused into a single molecule (F1-V). Multiple research groups have shown that immunizing with both antigens provides strong protection in a range of animal models.¹¹

An important advantage of combining the two antigens is insurance against naturally occurring variants. Some Y. pestis strains lack the F1 capsule entirely but remain virulent. A vaccine targeting only F1 would leave you vulnerable to those strains, while including V broadens the coverage.¹¹ In mouse studies, higher antibody levels against both F1 and V were each linked to better odds of surviving plague challenge. Each tenfold increase in antibody titer to V was associated with roughly a 2.5-fold increase in survival odds against either bubonic or pneumonic plague.¹²

A phase 1 trial tested a recombinant F1 and V vaccine in healthy human volunteers and found that virtually all subjects produced specific antibodies after a priming dose, with levels peaking after a booster given three weeks later. When sera from those volunteers were passively transferred to mice, protective immunity followed, and the degree of protection correlated with antibody levels.¹³ These results are encouraging, and versions of the F1-V vaccine have passed through Phase I and Phase II clinical trials, though final Phase II results have not been publicly released as of the most recent published reviews.⁸

Why Getting a Plague Vaccine Approved Is So Difficult

Several factors conspire to make plague vaccine development painfully slow, even when the science looks promising in trials.

First, there is the ethical problem of testing efficacy. You cannot deliberately expose humans to a potentially lethal pathogen like Y. pestis to see whether a vaccine works, and naturally occurring plague cases are too rare and scattered in most of the world to support conventional large-scale efficacy trials. This means any plague vaccine heading toward licensure in the United States would need to be approved under the FDA’s Animal Rule, which requires demonstrating efficacy in well-characterized animal models instead of human challenge studies.¹⁴ Developing the validated animal models and correlates of protection needed to satisfy this pathway takes years.

Second, the bacterium itself is a formidable adversary for the immune system. Y. pestis has evolved sophisticated mechanisms to dodge and suppress immune defenses. Early in infection, it uses a molecular syringe called the type III secretion system to inject proteins directly into host immune cells, which blocks those cells from swallowing and destroying the bacteria, and also suppresses their ability to signal for reinforcements. On top of that, the bacterium changes the structure of its outer membrane when it enters the warm mammalian body, which reduces the immune system’s ability to detect and respond to the invader. The result is that the bacteria can spread throughout the body before the immune system mounts an effective defense.¹⁵ A successful vaccine has to prime the immune system well enough to overcome these built-in countermeasures.

Third, identifying reliable markers that predict whether someone is actually protected after vaccination has been an ongoing challenge. Researchers have worked to develop laboratory assays that can predict survival without having to challenge a live animal. One approach measures how well serum from vaccinated subjects can protect immune cells from being killed by plague bacteria in a dish, and this has shown a strong association with survival in animal models.¹⁶ Nailing down these correlates of protection is not just an academic exercise; regulators need them before they can approve a vaccine under the Animal Rule pathway.

mRNA Vaccines Enter the Picture

The success of mRNA vaccines against COVID-19 has opened a new front in plague vaccine research. While the mRNA platform has been proven primarily against viral targets, researchers are now exploring whether it can work against bacteria, and early results against Y. pestis are intriguing.

One group designed an mRNA vaccine encoding the F1 capsule antigen, packaged in lipid nanoparticles. In mice, a single dose triggered both antibody and cellular immune responses and provided complete protection against lethal Y. pestis infection.¹⁷ The appeal of single-dose protection is obvious in outbreak settings where you may not get a second chance to vaccinate people.

A more recent study went further by designing a bivalent mRNA vaccine that encodes both F1 and modified versions of the V antigen. This combination approach produced significant immune activation in mice and provided substantial protection against intranasal plague challenge, which models the pneumonic form of the disease. The researchers described this as the first comprehensive evaluation of mRNA constructs encoding both key plague antigens.¹⁸ These are still early-stage, mouse-only results, and scaling up from mice to humans is never guaranteed, but the speed and flexibility of the mRNA platform could help accelerate progress.

Reaching the Lungs Through the Nose

One persistent shortcoming of plague vaccines, both old and new, is that injecting a vaccine into the arm tends to build strong immune defenses in the blood but not necessarily in the lungs. Since pneumonic plague attacks the respiratory tract, that gap can be the difference between protection and failure. Research comparing intranasal vaccines to injected ones found that delivering plague antigens into the respiratory tract produced antibody responses comparable in strength to intramuscular injection, with the added benefit of generating antibodies directly in the airways.¹⁹

A study using F1-V formulated with a mucosal adjuvant and given intranasally to mice found that this approach triggered high levels of IgA antibodies in the lungs, something that neither intranasal F1-V alone nor injected F1-V managed to do.²⁰ The practical implication is that the route of delivery may matter as much as the antigen itself, and that nasal spray or inhalable vaccines could eventually be part of the puzzle for pneumonic plague protection. None of these mucosal approaches has reached human trials yet, but the idea of priming immunity right where the pathogen strikes is driving a growing body of work.

Vaccinating Prairie Dogs to Break the Chain

One area where plague vaccination has actually been put into practice is wildlife conservation. In the western United States, plague periodically tears through prairie dog colonies, sometimes wiping them out entirely. Because prairie dogs are a keystone species for grassland ecosystems, and because endangered animals like the black-footed ferret depend on them for food and shelter, the U.S. government has invested in vaccinating prairie dogs against plague.

The approach is elegantly low-tech: vaccine-laced peanut butter bait pellets are scattered across prairie dog colonies. The bait contains a recombinant raccoon poxvirus engineered to express the F1 antigen of Y. pestis. In a controlled study, prairie dogs that ate the vaccine bait developed significant antibody responses and survived plague challenge at much higher rates than unvaccinated controls.²¹ A larger field trial confirmed that distributing the oral vaccine across prairie dog colonies before plague arrived prevented the colony collapses that otherwise follow an outbreak.²²

This sylvatic plague vaccine program is now an active wildlife management tool in parts of the American West. It is a rare bright spot in plague vaccinology, a setting where the science has actually translated into real-world deployment. The program also serves as a kind of proof of concept for oral plague vaccines, though the leap from prairie dogs to humans involves an entirely different set of safety and regulatory requirements.

How Y. pestis Changes Its Disguise With Temperature

One of the more remarkable features of Y. pestis that complicates vaccination is its ability to remodel itself depending on temperature. When the bacterium lives in the flea gut at ambient temperature, its outer membrane has one molecular signature. When it enters a warm-blooded host and encounters mammalian body temperature, it alters the structure of a key component of its outer surface. This modification drastically reduces the ability of the host’s innate immune sensors to recognize the bacterium as a threat, buying the pathogen time to multiply and spread before the immune system sounds the alarm.¹⁵

Researchers have tried to turn this weakness into an advantage. By engineering live vaccine strains with a mutation that locks the outer membrane into a less-stimulating form, they have been able to create candidate vaccines that are both safer (less likely to provoke excessive inflammation) and still protective.¹⁴ It is a clever approach: using the pathogen’s own evolutionary trick against it. Live attenuated vaccines with these kinds of rational genetic modifications represent one more track in the broader effort to create a next-generation plague vaccine, alongside subunit and mRNA approaches. The field is pursuing multiple strategies in parallel partly because no single approach has yet checked every box: safe, durable immunity, protection against both bubonic and pneumonic forms, and practical to manufacture and distribute in the resource-limited settings where plague still kills.